n-probnp在心衰诊断、预后、治疗的管理-课件，幻灯，PPTPPT.ppt

N-proBNP在心衰诊断、预后、治疗的管理; 内 容;在初级保健中被误诊为心力衰竭的比例： - Framingham: 40% (McKee 1971) - Boston: 42% (Carlson 1985) - Kuopio: 50% (Remes 1991) 急诊室中25-50%的失代偿心力衰竭病人被误诊 ;Independent predictors of acute heart failure in dyspneic patients in the emergency department 急诊室呼吸困难患者急性心力衰竭的独立预测因素; 诊断心衰的三大常规; BNP 和 NT-proBNP的检测分析;NT-proBNP用于急性呼吸困难患者诊断的灰色地带值;Diagnoses associated with an intermediate NT-proBNP concentration but without acute heart failure as cause of their dyspnea in ICON.ICON 研究中NT-proBNP中度升高但无急性心力衰竭患者的呼吸困难原因;体征; 内 容;急性心力衰竭, 5000 pg/ml 是短期预后的界值;Januzzi et al. Arch Intern Med 2006;NT-proBNP and Therapy Monitoring for Acutely Destabilized HF急性不稳定性心力衰竭的NT-proBNP监测;NT-proBNP in acute HF;对急性失代偿性心衰住院患者治疗反应的检测;Algorithm for use of NT-proBNP during hospitalization for acute HF急性心力衰竭住院期间的NT-proBNP应用流程; NT-proBNP与慢性性心衰的预后; NT-proBNP与慢性性心衰的预后; 内 容; 检测NT-proBNP能指导急性失代偿性心衰住院患者的治疗吗？;The Trial of Intensified vs Standard Medical Therapyin Elderly Patients With Congestive Heart Failure (TIME-CHF); ACEI or ARB and -Blocker Doses Duringthe Study There were no significant differences between the 2 treatment groups by BNP level (P=.30). ; TIME-CHF: Primary and Secondary  Outcomes ;;;;PRIMA-study;Total Mortality ;Secondary analysis;On NT-proBNP target analysis: Primary endpoint;On NT-proBNP target: Mortality (%);Conclusions;血浆中利钠肽:在HF诊断和慢性HF患者管理 （结束语）;Thank you;There were no significant differences between the 2 treatment groups by N-terminal BNP level (P=.30).